Genmab Announces that Janssen has Submitted a Type II Variation Application to the European Medicines Agency for use of Subcutaneous DARZALEX® (daratumumab) in Patients with Light-chain (AL) amyloidosisGlobeNewsWire • 11/05/20
Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/05/20
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)GlobeNewsWire • 10/30/20
Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim AnalysisGlobeNewsWire • 10/21/20
Genmab Announces Data to be Presented at SITC 35th Anniversary Annual MeetingGlobeNewsWire • 10/14/20
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020GlobeNewsWire • 10/13/20
Genmab: Still A Rising Star In Biotech, But Legal Dispute May Slow Down Growth Trajectory In The Near TermSeeking Alpha • 10/12/20
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with JanssenGlobeNewsWire • 09/22/20
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020Business Wire • 09/21/20
Genmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in Patients with Light-chain (AL) AmyloidosisGlobeNewsWire • 09/10/20
Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020GlobeNewsWire • 08/26/20
Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple MyelomaGlobeNewsWire • 08/20/20
Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.GlobeNewsWire • 08/20/20
Genmab A/S (GMAB) CEO Jan van de Winkel on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/13/20
Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaGlobeNewsWire • 07/31/20
